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Abstract
Objectives The association between periodontal disease and
adverse pregnancy outcomes (APO), primarily preterm birth
(PTB), is still controversially discussed in the literature.
Therefore, the aim of the present systematic review was to
analyze the existing literature on the potential association
between inflammatory mediators detected in gingival
crevicular fluid (GCF) and APO.
Materials and methods MEDLINE (PubMed) and EMBASE
databases were searched for entries up to April 2012 and
studies were selected by two independent reviewers.
Results The majority of the eight studies included con-
firmed a positive association between GCF mediators, such
as interleukin-1β, prostaglandin E2, and tumor necrosis
factor-alpha, and APO. Due to the heterogeneity and vari-
ability of the available studies, no meta-analysis could be
performed.
Conclusions A positive association between GCF inflam-
matory mediator levels and APO/PTB might be present but
the results need to be considered with great caution because
of the heterogeneity and variability among the studies.
Further studies with an adequate number of patients
allowing for an appropriate analysis are warranted to defi-
nitely confirm this association.
Clinical relevance The present findings suggest that an
association between GCF inflammatory mediator levels
and APO might exist.
Keywords Periodontal disease . Gingival crevicular fluid .
Inflammatory mediators . Adverse pregnancy outcomes .
Preterm birth
Introduction
Periodontal disease such as plaque-induced gingivitis and
periodontitis has been linked to several systemic conditions
such as cardiovascular disease, diabetes, respiratory disease,
and adverse pregnancy outcomes (APO), including primar-
ily preterm birth (PTB), low birth weight (LBW), miscar-
riage, or preeclampsia [1–3]. Although the causative
pathophysiological mechanisms behind these relationships
remain unclear, a low-grade systemic inflammation with
elevated levels of proinflammatory mediators has been pro-
posed to play a key role. Several studies have suggested that
patients affected by gingivitis or periodontitis produce
higher levels of proinflammatory mediators in gingival
crevicular fluid (GCF) compared to healthy subjects, includ-
ing interleukin-1 (IL-1), IL-6, tumor necrosis factor-alpha
(TNF-α), and prostaglandin E2 (PGE2) [4–6]. Animal stud-
ies, which used a subcutaneous tissue chamber model to in-
vestigate the effect of a localized challenge of Porphyromonas
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gingivalis on the fetoplacental unit, have demonstrated a local
increase in bacterial lipopolysaccharides (LPS) and PGE2,
resulting in fetal death and/or fetal growth restriction [7, 8].
Offenbacher et al. postulated that periodontal disease caused
by gram-negative anaerobic bacteria may have a negative
influence on the course of pregnancy through the production
of proinflammatory mediators [9]. Therefore, attempts to use
mediators as diagnostic markers to predict pregnancy out-
comes have been made [10, 11].
APO, in particular PTB, continue to be a significant
public health issue in both developed and developing coun-
tries. They represent approximately 10 % of all live births
worldwide [12] and account for 28–75 % of all perinatal
deaths and over 50 % of all severe developmental disability
in children worldwide [13–15]. Therefore, the prevention of
APO is an important goal for public health services and thus
warranting further research.
Systematic reviews published on the topic of an association
between APO and periodontal disease concluded that, current-
ly, despite a consistent association between periodontal disease
and PTB/LBW, it is impossible to prove a causative relation-
ship between these two conditions and the findings should be
interpretedwith great caution until the sources of heterogeneity
among studies are more evident [3, 16]. Variability among
study designs, diagnostic methods, and definitions of peri-
odontal disease or APO makes it difficult to compare the
published data. Although there seems to exist evidence of an
association between periodontal disease and APO [3], a recent
review was not able to demonstrate reductions in PTB after
periodontal therapy in clinical trials [17].
Although, at present, the exact pathophysiological mech-
anism of a putative causative relationship between periodon-
tal diseases and APO is unknown, the following hypotheses
have attempted to provide some explanation [18]:
1. translocation of periodontal pathogens to the fetoplacental
unit;
2. influence of LPS from periodontal bacteria on the
fetoplacental unit;
3. role of inflammatory mediators (IL-1, IL-6, TNF-α, and
PGE2) in GCF on the fetoplacental unit.
Furthermore, until now, to the best of our knowledge, no
systematic review of the literature is available on the potential
association between GCF inflammatory mediators and APO.
Therefore, the aim of the present systematic review was to
analyze the existing literature on the potential association
between inflammatory mediators detected in GCF and APO.
Materials and methods
This systematic review has been conducted adhering wher-
ever possible to the guidelines of the PRISMA statement
[19] and Needleman [20] by defining a focused question and
specific inclusion criteria. An electronic search into two
different databases as well as a structured quality assessment
was performed. Due to the heterogeneity and variability of
the included studies, no meta-analysis could be performed.
Focused question
The focused question “Are elevated GCF inflammatory
mediator levels during pregnancy associated with APO?”
was defined adhering to the PICO format:
– Population: pregnant women
– Intervention: no intervention was conducted (except for
Offenbacher et al. [21])
– Comparison: elevated and non-elevated GCF inflamma-
tory mediator levels
– Outcomes: APO yes/no
Study selection
The inclusion criteria were as follows:
– Studies with pregnant women or women with recent
delivery
– Collection of GCF and analysis of GCF inflammatory
mediators
– Investigation of APO
– At least 18 subjects included in the study
– Full text written in English
– Study design: randomized controlled trials, case–control
studies, or case series
Search strategy
An electronic search into the MEDLINE (PubMed) and
EMBASE databases for articles published up to and including
April 12, 2012 was performed. The search strategy applied
was: “gingival fluid AND pregnancy” (search details: “gingi-
va” [MeSH Terms] OR “gingiva” [All Fields] OR “gingival”
[All Fields]) AND (“body fluids” [MeSH Terms] OR (“body”
[All Fields] AND “fluids” [All Fields]) OR “body fluids” [All
Fields] OR “fluid” [All Fields]) AND (“pregnancy” [MeSH
Terms] OR “pregnancy” [All Fields]). A manual search was
performed by screening the reference lists of the selected
studies for publications not listed in the electronic databases.
A search for gray literature, i.e., possibly relevant but not yet
published studies, was also conducted.
Validity assessment
The electronic search as well as the screening of the search
results according to the inclusion criteria was independently
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conducted by two reviewers (P.S. and R.A.). The manual
search and the search for gray literature were performed by
P.S. Any possible discrepancies were resolved by discussion
between the two reviewers.
Quality assessment
The following points were focused:
– Sample size
– Definitions of APO (were the investigated APO clearly
defined?)
– Assessment of APO and description of criteria applied
to confirm APO (were adequate means used to confirm
APO?)
– Data presentation of GCF mediator levels and GCF
sampling methods
– Assessment of periodontal conditions (which diagnostic
means were used to assess periodontal disease?)
– Definition of periodontal disease (was a clear definition
of periodontal disease described?)
– Management of confounders (was the study performed
with a thorough control for confounders?)
Results
Selection process of the included publications
The search into the PubMed and EMBASE databases
resulted in the identification of 245 titles, of which 27 titles
were identified in both databases. The manual search and
the search for gray literature did not result in the detection of
further articles or data. Initial screening of these 245 titles
resulted in the consideration of 59 abstracts. Independent
screening of these 59 abstracts with respect to the inclusion
criteria resulted in further consideration of eight publica-
tions. For these eight publications, full-text articles were
obtained and analyzed. All eight publications finally
matched the inclusion criteria (Fig. 1). For each step of the
selection process, agreement on the included studies was
reached in 100 % between the two reviewers. The studies
which remained after the last selection (n=8) are presented
in Table 1.
Quality assessment
The sample size varied widely among publications; two stud-
ies included 18–30 subjects [22, 23], two studies included 31–
60 subjects [24, 25], one study included 61–100 subjects [26],
and three studies included 101–128 subjects [21, 27, 28].
Although differences exist among studies concerning the
choice of investigated APO, these were always clearly
defined; while a majority of the studies reported preterm
low birth weight (PLBW) [24, 26–28], one examined PTB
and LBW separately [23] and one examined only PTB [21].
Two authors reported preeclampsia [22, 25].
With respect to the description of the criteria applied to
confirm APO, three studies were classified as adequate,
which presented a clear description of the criteria applied
to confirm either PLBW [23] or preeclampsia [22, 25]. Five
studies, which did not report how the gestational age was
determined in order to confirm PLBW, were classified as
unclear [21, 24, 26–28].
Data presentation of GCF mediator levels also differs
among publications. A majority of the authors applied ade-
quate methods and reported concentrations [22–26, 28],
although it has to be mentioned that only two of these
studies presented a time specification concerning the GCF
sampling [22, 25]. Two studies were classified as inade-
quate, reporting either no defined volume and no data about
sampling and processing [27] or mass/volume eluent, which
results in an irrelevant concentration [21].
Concerning the assessment of periodontal conditions, a
majority of the studies applied adequate diagnostic methods
based on full-mouth probing measurements [21, 23–25, 27,
28], whereas two studies applied inadequate diagnostic
methods conducting only partial mouth recordings such as
Community Periodontal Index of Treatment Needs (CPITN)
[26] or examining only the Ramfjord index teeth [22].
A clear definition of periodontal disease was presented in
five studies [23, 25–28], but not in the other three [21, 22,
24]. Although Offenbacher et al. [24] reported the Extent
and Severity Index, this study lacks an explicit definition of
thresholds for periodontal disease.
Regarding the management of confounders, only three
studies were performed with control for relevant con-
founders such as maternal age, race, smoking, alcohol in-
take, drug use, socioeconomic status, genitourinary
infections, and previous history of PLBW [21, 25, 28].
Five studies did not report a thorough control for con-
founders [22–24, 26, 27], although Tarannum et al. [23]
excluded patients with several known risk factors for
PLBW and, in the study by Oettinger-Barak et al. [22], test
and control subjects were matched for age and socioeco-
nomic status (Table 2).
Association between GCF inflammatory mediators
and APO
In a study examining 40 women with either PTB/LBW or
normal birth weight (NBW), Offenbacher et al. found a con-
sistent association between pregnancy outcome and different
periodontal parameters [24]. PLBWmothers showed a slight-
ly worse but not statistically significant periodontal disease
status compared with NBW mothers (mean extent scores
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(clinical attachment level (CAL) ≥4 mm) of 43 and 40 %,
respectively). A significant twofold elevation in the GCF
PGE2 levels and a tendency, although not significant, for
elevated IL-1β levels were found in mothers with PLBW as
well as significantly higher levels for all tested
periodontopathogenic bacteria including Aggregatibacter
actinomycetemcomitans, Porphyromonas gingivalis,
Treponema denticola, and Tannerella forsythia. In addition,
this study reported an inverse relationship between GCF PGE2
levels and birth weight within primiparous women.
The results of a study with 84 women with PLBWand 44
controls by Konopka et al. showed a significantly higher
frequency of periodontitis (chronic and aggressive) in the
test group [27]. In all women with PLBW, there were
significantly higher levels of IL-1β and PGE2 in GCF, and
in primiparous women, there was also a higher PGE2 level
in the blood serum, compared to the controls. Secretion of
these proinflammatory mediators in whole blood after
Escherichia coli LPS stimulation showed no significant
differences between groups. Furthermore, an inverse asso-
ciation between GCF PGE2 concentration and birth weight
in primiparous women was found in this study.
In a case–control study including 92 women, Carta et al.
reported significantly worse periodontal disease status as well
as significantly higher PGE2 and IL-1β GCF levels in PLBW
mothers compared with NBW controls [26]. In this study, only
10 % of subjects were free of any periodontal disease (CPITN
score=0).
Tarannum et al. conducted a pilot investigation including
22 pregnant women with normal pregnancy outcomes and
APO and explored the possible use of the GCF PGE2 level
as a risk predictor of PLBW [23]. They reported higher
mean GCF PGE2 levels in mothers of PTB and LBW infants
than in mothers of NBW and full-term birth infants, but this
difference was not significant.
Noack et al. could not confirm periodontitis as a risk
factor for PLBW in a case–control study with 59 pregnant
women with a high risk for PLBW and 42 control women
[28]. No significant differences in periodontal status and
levels of periodontopathogenic bacteria such as A.
actinomycetemcomitans, Fusobacterium nucleatum, P.
gingivalis, Prevotella intermedia, and T. forsythia between
the groups were reported. To be mentioned is a tendency to
higher GCF IL-1β levels in the case group, which was not
significantly different from controls. The prevalence of
moderate to severe periodontitis and generalized periodon-
titis in this study sample was low.
Concerning a possible relationship between GCF media-
tors and preeclampsia, several investigations show positive
results. Canakci et al. reported a highly significant associa-
tion between severe periodontitis and mild to severe pre-
eclampsia in a case–control study with 59 pregnant women
[25]. A majority of the women in this study presented with
mild to severe periodontal disease. All measured mediator
levels (IL-1β, TNF-α, and PGE2) were significantly higher
in preeclamptic than normotensive women in both GCF and
serum and a significant positive correlation between GCF
and serum mediator levels was found. A negative significant
correlation was also found between all GCF and serum
mediator levels and LBW (except for PGE2 in serum).
Potentially relevant 
titles identified from 
electronic search
(n = 245)
•Publications 
excluded on the 
basis of title 
evaluation              
(n = 186)
Potentially relevant 
abstracts retrieved 
for further analysis 
(n = 59)
•Publications 
excluded on the 
basis of abstract 
evaluation           
(n = 51)
Potentially relevant 
full-text articles 
retrieved for more 
detailed evaluation 
(n = )
•Publications 
excluded on the 
basis of full-text 
evaluation           
(n = 0) 
Publications 
included in the 
present review 
(n = ) 
8
8
Fig. 1 Search strategy of the
relevant publications
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Oettinger-Barak et al. examined 15 healthy pregnant women
and 15 with preeclampsia and found significantly greater
periodontal breakdown as well as significantly higher GCF
levels of proinflammatory mediators IL-1β, TNF-α, and
PGE2 in the preeclampsia group compared to controls
[22]. Furthermore, periodontal parameters (probing pocket
depth (PPD) and CAL) correlated partially with mediator
levels in GCF.
Investigating the effect of periodontal therapy on GCF
mediator levels and pregnancy outcomes, Offenbacher et al.
conducted a randomized, delayed-treatment, controlled pilot
trial [21]. They evaluated the effects of scaling and root
planing during the second trimester and the use of a sonic
power toothbrush on the rate of PTB and clinical parameters
such as oral pathogens, GCF, and serum levels of
proinflammatory mediators and changes in periodontal status.
Their results showed that periodontal therapy lead to signifi-
cant improvements in clinical parameters and significantly
decreased GCF IL-1β levels and the odds ratio for PTB.
Discussion
The present systematic review has attempted to evaluate the
existing literature concerning a potential association be-
tween GCF inflammatory mediators and APO. The findings
of the present systematic review suggest a positive associa-
tion between GCF inflammatory mediators and APO. The
majority of the included studies confirmed a significant
positive association between inflammatory mediators such
as IL-1β, PGE2, and TNF-α in GCF and either PLBW [23,
24, 26, 27] or preeclampsia [22, 25]. Two studies were not
able to prove a significant relationship between GCF medi-
ator levels and PLBW in spite of a tendency for higher GCF
IL-1β and PGE2 levels in PLBW women compared to
controls [23, 28]. The degree of methodological quality of
the studies was not crucial for the outcome being significant
or nonsignificant. The low prevalence of moderate to severe
periodontitis and generalized periodontitis in the study by
Noack et al. [28] and the inclusion of only women with
clinically healthy gingiva in the study by Tarannum et al.
[23] might have influenced these results. In addition, several
studies have shown an inverse association between GCF
PGE2, IL-1β, or TNF-α levels and birth weight [24, 25,
27]. These results appear to indicate that periodontal disease
during pregnancy may result in enhanced systemic exposure
of inflammatory mediators of oral origin, which may con-
tribute to APO.
The heterogeneity of outcomes among selected studies
may be due to several possible sources. First of all, different
APO were defined and investigated (PLBW, PTB, LBW,
and preeclampsia). Analyzing GCF, different inflammatory
mediators were reported (mainly PGE2, IL-1β, and TNF-α).
In addition, different methods of data presentation of GCF
mediator levels were used. While a majority of the authors
reported concentrations (mass/volume GCF or mass/sample)
of mediator levels, some did not measure GCF volume and,
therefore, were not able to report relevant concentrations.
Methods for the assessment of periodontal conditions and
definitions of periodontal disease varied widely and only
few studies reported distinct thresholds for the definition of
periodontal disease. Furthermore, the periodontal disease
status of the included subjects showed high diversity. Only
three studies conducted a thorough control for potential
confounders. Adjustment for confounding variables is of
high importance to avoid study bias. Thus, the association
between periodontitis and PLBW supported in some studies
may be due to inadequate adjustment. Due to the heteroge-
neity and variability of the available studies, no analysis
could be performed evaluating the association between
GCF mediators and APO.
The previously discussed findings appear to support the
hypothesis that an association of periodontal disease and
APO could result from the action of a periodontal reservoir
of inflammatory mediators (IL-1, IL-6, TNF-α, and PGE2)
on the fetoplacental unit. This hypothesis is further
supported by studies which suggested that PGE2 and cyto-
kines such as IL-1 and TNF-α play an important role in the
normal physiologic process of parturition as well as in
pathologic prematurity [29–32]. IL-1β is a potent stimulator
of the prostaglandin synthesis by decidua and amnion and
was the first cytokine implicated in the onset of labor in the
presence of infection [33–35]. Amniotic fluid levels of
PGE2 rise steadily throughout pregnancy until a critical
threshold level is reached to induce labor, cervical dilation,
and delivery [36]. Romero et al. observed elevated levels of
PGE2 as a consistent and reproducible fact of PTB, even in
the absence of clinical or subclinical genitourinary tract
infection and they postulated that the majority of PTB cases
are probably caused by an infection of unknown origin [37].
In addition, elevated proinflammatory cytokines in amniotic
fluid such as TNF-α or IL-6 are related to severe neurolog-
ical outcome in preterm neonates, including periventricular
leukomalacia and cerebral palsy.
However, a linear causal relationship between GCF in-
flammatory mediators or periodontal disease in general and
APO has not yet been demonstrated. Controversial hypoth-
eses do not support a linear causal relationship but rather
suggest some common features between periodontal disease
and APO, mainly based on genetically determined individ-
ual predisposition to yield a hyperinflammatory response to
bacterial challenge [38, 39]. This hyperinflammatory re-
sponse may in turn alter the patient’s inflammatory pheno-
type, thus placing the patient at risk for both disorders. This
possibility gives rise to some new questions: Does advanced
periodontitis rather play a role as a susceptibility marker for
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APO than as a causal factor? Does a genetically determined
hyperinflammatory response that predisposes an individual
to periodontal disease also predispose to other multifactorial
diseases which are related to inflammation?
The hypothesis of a genetically determined hyperinflam
matory trait appears to be supported by the results of a study
by Damaré et al. who stated that, despite a significant positive
association between PGE2 levels in GCF and amniotic fluid,
the low levels of PGE2 in amniotic fluid do not support the
assumption of a translocation of GCF PGE2 to the fetal
placental unit [40]. Thus, it seems that the patient-specific
state of systemic responsiveness and monocytic response de-
termines both the GCF and amniotic fluid PGE2 levels. They
concluded that GCF levels of PGE2 may be used to provide an
indirect estimate of the amniotic fluid levels of PGE2 and may
serve as a risk factor, since amniotic fluid PGE2 levels can be
predictive of preterm delivery.
Converse conclusions come from the study by Konopka
et al. [27] who could not confirm a higher secretion of IL-1β
and PGE2 in whole blood after bacterial LPS stimulation in
PLBW women. This lack of significant differences suggests
that more frequent occurrence of a hyperactive cell pheno-
type synthesizing these mediators is rather not responsible
for PLBW. In contrast, they found a significantly higher
secretion of IL-1β after stimulation in patients with gingi-
vitis and periodontitis compared to subjects with a healthy
periodontium, apparently indicating that IL-1β secretion is
mainly due to exposition of special cells to bacterial prod-
ucts and that PLBW cannot be related with frequent inci-
dence of a hyperactive cell phenotype.
The conflicting results on the causal relationship between
GCF inflammatory mediators and APO may be explained
by the fact that the majority of the studies investigating a
correlation between mediator levels in GCF and serum
either failed to show a statistically significant correlation
between mediator levels in GCF and serum or they only
found a weak statistically not significant correlation [23,
41]. Only Canakci et al. reported a statistically significant
correlation between GCF and serum mediator levels [25].
Fiorini et al. [41] found a low correlation between GCF and
serum mediator levels. Consequently, their results have
failed to support the hypothesis that periodontal disease
may lead to a low-grade systemic inflammatory status in
pregnant women. On the other hand, a limitation of the
mentioned study is the fact that severe periodontal destruc-
tion was only detected in a small percentage of the subjects
and, thus, it cannot be excluded that the results might have
been influenced by including only women with severe
periodontitis.
The findings of the study by Fiorini et al. are in agree-
ment with other studies which also found low serum levels
of IL-1β, IL-6, IL-8, and TNF-α in pregnant women [21].
Few other studies have assessed concomitantly GCF and
systemic inflammatory mediator levels independent of preg-
nancy. Orozco et al., who evaluated serum and GCF medi-
ator levels in 10 gingivitis and 10 periodontitis patients,
found detectable levels of IL-1β only in GCF [42].
Trombelli et al. also reported similar results of IL-1β in
experimentally induced gingivitis [43]. Fentoglu et al. eval-
uated the serum and GCF levels of IL-1β, IL-6, and TNF-α
in 123 hyperlipidemic patients and 68 systemically healthy
controls and found consistently higher serum than GCF
levels of all mediators evaluated, irrespective of periodontal
status or lipid status [44].
Offenbacher et al. concluded that periodontal therapy
during pregnancy leads to clinical improvements such as
reduction of plaque index, gingival index, and PPD and
lower GCF levels of PGE2 and IL-1β [21, 45]. It could be
confirmed that initial periodontal treatment during pregnan-
cy leads to a significantly decreased incidence odds ratio for
PTB and that periodontal treatment during pregnancy is
safe. The reported finding that periodontal treatment is
associated with decreased GCF mediator levels is in agree-
ment with a recent study, which examined a wide range of
GCF mediators including IL-1α, IL-1β, IL-6, and IL-
8 [46]. The fact that periodontal treatment has been
shown to lead to decreased GCF mediator levels and
PTB incidence further supports the hypothesis of a linear
causal relationship between GCF mediators and APO. On
the other hand, it should be kept in mind that recent
studies have failed to confirm a statistically significant
decrease in the incidence of PTB, despite the fact that
they did not investigate proinflammatory mediators in
GCF [47, 48] and are also supported by the conclusion
of a recent systematic review, indicating that treatment of
maternal periodontal disease does not seem to decrease
the risk of PTB and/or LBW [17].
Conclusions
Taken together, the present findings indicate that:
(a) A positive association between GCF inflammatory me-
diator levels and APO/PTB might be present, but the
results need to be considered with great caution be-
cause of the heterogeneity and variability among the
studies.
and
(b) Further studies with an adequate number of patients,
allowing for an appropriate analysis, are warranted to
definitely confirm this association.
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